[1] Chen WS, Leung CM, Pan HW, et al. Silencing of miR11 and miR133a2 cluster expression by DNA hypermethylation in colorectal cancer[J]. Oncol Rep, 2012, 28 (3): 1069-1076.
[2] Tao J, Wu D, Xu B, et al. microRNA133 inhibits cell proliferation, migration and invasion in prostate cancer cells by targeting the epidermal growth factor receptor[J]. Oncol Rep, 2012, 27(6): 1967-1975.
[3] Kojima S, Chiyomaru T, Kawakami K, et al. Tumour suppressors miR1 and miR133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer[J]. Br J Cancer, 2012, 106(2): 405-413.
[4] Kano M, Seki N, Kikkawa N, et al. miR145, miR133a and miR133b: tumorsuppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma[J]. Int J Cancer, 2010, 127(12): 2804-2814.
[5] Kawakami K, Enokida H, Chiyomaru T, et al. The functional significance of miR1 and miR133a in renal cell carcinoma[J]. Eur J Cancer, 2012, 48(6): 827-836.
[6] Chiyomaru T, Enokida H, Tatarano S, et al. miR145 and miR133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer[J]. Br J Cancer, 2010, 102(5): 883-891.
[7] Cui Q, Yu Z, Purisima EO, et al. Principles of microRNA regulation of a human cellular signaling network[J]. Mol Syst Biol, 2006, 2: 46.
[8] Mutallip M, Nohata N, Hanazawa T, et al. Glutathione Stransferase P1 (GSTP1) suppresses cell apoptosis and its regulation by miR133alpha in head and neck squamous cell carcinoma (HNSCC)[J]. Int J Mol Med, 2011, 27(3): 345-352.
[9] Nohata N, Hanazawa T, Kikkawa N, et al. Caveolin1 mediates tumor cell migration and invasion and its regulation by miR133a in head and neck squamous cell carcinoma[J]. Int J Oncol, 2011, 38(1): 209-217.
[10] Wang H, An H, Wang B, et al. miR133a represses tumour growth and metastasis in colorectal cancer by targeting LIM and SH3 protein 1 and inhibiting the MAPK pathway[J]. Eur J Cancer, 2013, 49(18): 3924-3935.
[11] Cui W, Zhang S, Shan C, et al. microRNA133a regulates the cell cycle and proliferation of breast cancer cells by targeting epidermal growth factor receptor through the EGFR/Akt signaling pathway[J]. FEBS J, 2013, 280(16): 3962-3974.
[12] Moriya Y, Nohata N, Kinoshita T, et al. Tumor suppressive microRNA133a regulates novel molecular networks in lung squamous cell carcinoma[J]. J Hum Genet, 2012, 57(1): 38-45.
[13] Wen D, Li S, Ji F, et al. miR133b acts as a tumor suppressor and negatively regulates FGFR1 in gastric cancer[J]. Tumour Biol, 2013, 34(2): 793-803.
[14] Hu G, Chen D, Li X, et al. miR133b regulates the MET protooncogene and inhibits the growth of colorectal cancer cells in vitro and in vivo[J]. Cancer Biol Ther, 2010, 10(2): 190-197.
[15] Wong TS, Liu XB, ChungWai Ho A, et al. Identification of pyruvate kinase type M2 as potential oncoprotein in squamous cell carcinoma of tongue through microRNA profiling[J]. Int J Cancer, 2008, 123(2): 251-257.
[16] Qin W, Dong P, Ma C, et al. MicroRNA133b is a key promoter of cervical carcinoma development through the activation of the ERK and AKT1 pathways[J]. Oncogene, 2012, 31(36): 4067-4075.
[17] Crawford M, Batte K, Yu L, et al. MicroRNA 133B targets prosurvival molecules MCL1 and BCL2L2 in lung cancer[J]. Biochem Biophys Res Commun, 2009, 388(3): 483-489.
[18] Liu L, Shao X, Gao W, et al. MicroRNA133b inhibits the growth of nonsmallcell lung cancer by targeting the epidermal growth factor receptor[J]. FEBS J, 2012, 279(20): 3800-3812.
[19] Chiyomaru T, Enokida H, Kawakami K, et al. Functional role of LASP1 in cell viability and its regulation by microRNAs in bladder cancer[J]. Urol Oncol, 2012, 30(4): 434-443.
[20] Yoshino H, Chiyomaru T, Enokida H, et al. The tumoursuppressive function of miR1 and miR133a targeting TAGLN2 in bladder cancer[J]. Br J Cancer, 2011, 104(5): 808-818.
[21] Nohata N, Hanazawa T, Kikkawa N, et al. Identification of novel molecular targets regulated by tumor suppressive miR1/miR133a in maxillary sinus squamous cell carcinoma[J]. Int J Oncol, 2011, 39(5): 1099-1107.
[22] Uchida Y, Chiyomaru T, Enokida H, et al. MiR133a induces apoptosis through direct regulation of GSTP1 in bladder cancer cell lines[J]. Urol Oncol, 2013, 31(1): 115-123.
[23] SainzJaspeado M, LagaresTena L, Lasheras J, et al. Caveolin1 modulates the ability of Ewing′s sarcoma to metastasize[J]. Mol Cancer Res, 2010, 8(11): 1489-1500.
[24] Joshi B, Strugnell SS, Goetz JG, et al. Phosphorylated caveolin1 regulates Rho/ROCKdependent focal adhesion dynamics and tumor cell migration and invasion[J]. Cancer Res, 2008, 68(20): 8210-8220.
[25] Zhao L, Wang H, Liu C, et al. Promotion of colorectal cancer growth and metastasis by the LIM and SH3 domain protein 1[J]. Gut, 2010, 59(9): 1226-1235.
[26] Kinoshita T, Nohata N, WatanabeTakano H, et al. Actinrelated protein 2/3 complex subunit 5 (ARPC5) contributes to cell migration and invasion and is directly regulated by tumorsuppressive microRNA133a in head and neck squamous cell carcinoma[J]. Int J Oncol, 2012, 40(6): 1770-1778.
[27] Suzuki S, Yokobori T, Tanaka N, et al. CD47 expression regulated by the miR133a tumor suppressor is a novel prognostic marker in esophageal squamous cell carcinoma[J]. Oncol Rep, 2012, 28(2): 465-472.
[28] Yamamoto H, Kohashi K, Fujita A, et al. Fascin1 overexpression and miR133b downregulation in the progression of gastrointestinal stromal tumor[J]. Mod Pathol, 2013, 26(4): 563-571.
[29] Gan Y, Shi C, Inge L, et al. Differential roles of ERK and Akt pathways in regulation of EGFRmediated signaling and motility in prostate cancer cells[J]. Oncogene, 2010, 29(35): 4947-4958.
[30] PljesaErcegovac M, SavicRadojevic A, Dragicevic D, et al. Enhanced GSTP1 expression in transitional cell carcinoma of urinary bladder is associated with altered apoptotic pathways[J]. Urol Oncol, 2011, 29(1): 70-77.
[31] Xie JJ, Xu LY, Zhang HH, et al. Role of fascin in the proliferation and invasiveness of esophageal carcinoma cells[J]. Biochem Biophys Res Commun, 2005, 337(1): 355-362.
[32] Vignjevic D, Schoumacher M, Gavert N, et al. Fascin, a novel target of betacateninTCF signaling, is expressed at the invasive front of human colon cancer[J]. Cancer Res, 2007, 67(14): 6844-6853. |